Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 11/20 | 0.69 |
| ▸ | IKZF2 | Q9UKS7 | 8/20 | 0.57 |
| ▸ | GSPT1 | P15170 | 2/20 | 0.57 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.57 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.56 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.56 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30132173 | 1.00 | CRBN (0.69) | CRBNIKZF2GSPT1DDB1CYP2C19 | |
| Hydrochloric Acid SCHEMBL25280592 | 0.99 | CRBN (0.67) | CRBNIKZF2GSPT1DDB1CYP2C19 | |
| SCHEMBL29188614 | 0.91 | CRBN (0.66) | CRBNIKZF2GSPT1DDB1CYP2C19 | |
| SCHEMBL25227548 | 0.91 | CRBN (0.69) | CRBNGSPT1 | |
| SCHEMBL25228921 | 0.89 | CRBN (0.70) | CRBNIKZF2GSPT1DDB1CYP2C19 | |
| SCHEMBL24600532 | 0.88 | CRBN (0.69) | CRBNIKZF2GSPT1DDB1CYP2C19 | |
| SCHEMBL68272 | 0.88 | CRBN (0.72) | CRBNIKZF2GSPT1DDB1CYP2C19 | |
| SCHEMBL31117059 | 0.88 | CRBN (0.72) | CRBNIKZF2GSPT1DDB1CYP2C19 | |
| SCHEMBL25234569 | 0.88 | CRBN (0.69) | CRBNIKZF2GSPT1DDB1CYP2C19 | |
| SCHEMBL25469611 | 0.88 | CRBN (0.69) | CRBNIKZF2GSPT1DDB1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4446324-A1 | LIGAND COMPOUNDS FOR E3 UBIQUITIN LIGASE, PROTEIN DEGRADERS DEVELOPED ON BASIS OF LIGAND COMPOUNDS, AND USES THEREOF | Gluetacs Therapeutics (Shanghai) Co., Ltd. (CN) | 2024-10-16 | — | — | EP | claimed |
| WO-2023104155-A1 | LIGAND COMPOUNDS FOR E3 UBIQUITIN LIGASE, PROTEIN DEGRADERS DEVELOPED ON BASIS OF LIGAND COMPOUNDS, AND USES THEREOF | 标新生物医药科技(上海)有限公司 | 2023-06-15 | — | — | WO | claimed |
| CN-116239566-A | E3 ubiquitin ligase ligand compound, protein degradation agent developed based on ligand compound and application thereof | 标新生物医药科技(上海)有限公司 | 2023-06-09 | — | — | CN | claimed |
| US-20260078119-A1 | DEGRADER COMPOUNDS AND USES THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2026-03-19 | — | — | US | disclosed |
| US-20260028326-A1 | COMPOUND BASED ON ISOINDOLINE-SUBSTITUTED GLUTARIMIDE BACKBONE AND USE THEREOF | GLUETACS THERAPEUTICS SHANGHAI CO LTD (CN) | 2026-01-29 | — | — | US | disclosed |
| EP-4678638-A1 | NEW E3 UBIQUITIN LIGASE LIGAND, PROTEIN DEGRADATION AGENT AND USE THEREOF | Gluetacs Therapeutics (Shanghai) Co., Ltd. (CN) | 2026-01-14 | — | — | EP | disclosed |
| EP-4461730-A1 | PROTEIN DEGRADERS DEVELOPED ON BASIS OF BCL-2 FAMILY PROTEIN LIGAND COMPOUNDS AND USE THEREOF | Shanghaitech University (CN) | 2024-11-13 | — | — | EP | disclosed |
| EP-4446324-A1 | LIGAND COMPOUNDS FOR E3 UBIQUITIN LIGASE, PROTEIN DEGRADERS DEVELOPED ON BASIS OF LIGAND COMPOUNDS, AND USES THEREOF | Gluetacs Therapeutics (Shanghai) Co., Ltd. (CN) | 2024-10-16 | — | — | EP | disclosed |
| WO-2024188209-A1 | NEW E3 UBIQUITIN LIGASE LIGAND, PROTEIN DEGRADATION AGENT AND USE THEREOF | 标新生物医药科技(上海)有限公司 | 2024-09-19 | — | — | WO | disclosed |
| CN-117881668-A | Compound based on isoindoline substituted glutarimide skeleton and application thereof | 标新生物医药科技(上海)有限公司 | 2024-04-12 | — | — | CN | disclosed |
| WO-2024032689-A1 | COMPOUND BASED ON ISOINDOLINE-SUBSTITUTED GLUTARIMIDE BACKBONE AND USE THEREOF | 标新生物医药科技(上海)有限公司 | 2024-02-15 | — | — | WO | disclosed |
| WO-2023131118-A1 | PROTEIN DEGRADERS DEVELOPED ON BASIS OF BCL-2 FAMILY PROTEIN LIGAND COMPOUNDS AND USE THEREOF | 上海科技大学 | 2023-07-13 | — | — | WO | disclosed |
| WO-2023131118-A1 | PROTEIN DEGRADERS DEVELOPED ON BASIS OF BCL-2 FAMILY PROTEIN LIGAND COMPOUNDS AND USE THEREOF | 上海科技大学 | 2023-07-13 | — | — | WO | disclosed |
| CN-116396288-A | Protein degradation agent developed based on BCL-2 family protein ligand compound and application thereof | 上海科技大学 | 2023-07-07 | — | — | CN | disclosed |
| WO-2023104155-A1 | LIGAND COMPOUNDS FOR E3 UBIQUITIN LIGASE, PROTEIN DEGRADERS DEVELOPED ON BASIS OF LIGAND COMPOUNDS, AND USES THEREOF | 标新生物医药科技(上海)有限公司 | 2023-06-15 | — | — | WO | disclosed |
| WO-2023104155-A1 | LIGAND COMPOUNDS FOR E3 UBIQUITIN LIGASE, PROTEIN DEGRADERS DEVELOPED ON BASIS OF LIGAND COMPOUNDS, AND USES THEREOF | 标新生物医药科技(上海)有限公司 | 2023-06-15 | — | — | WO | disclosed |
| CN-116239566-A | E3 ubiquitin ligase ligand compound, protein degradation agent developed based on ligand compound and application thereof | 标新生物医药科技(上海)有限公司 | 2023-06-09 | — | — | CN | disclosed |
| WO-2023015283-A1 | COMPOSITIONS AND METHODS FOR SELECTIVE DEGRADATION OF ENGINEERED PROTEINS | CELGENE CORPORATION (US) | 2023-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260028326-A1 | COMPOUND BASED ON ISOINDOLINE-SUBSTITUTED GLUTARIMIDE BACKBONE AND USE THEREOF | CDR2, CYC1, CLN6 | CRBN 9/4885IKZF2 4650/4885GSPT1 1817/4885 |
| US-20260078119-A1 | DEGRADER COMPOUNDS AND USES THEREOF | CTTN, SRC, PTK2 | CRBN 145/4885IKZF2 2250/4885GSPT1 3722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.